Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1342 participants.

Also called NCT01237223

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,342 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01237223
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01237223. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2012-06-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Aliskiren/Amlodipine 150/2.5 mg
Intervention (Drug)
Aliskiren/amlodipine 150/5 mg
Intervention (Drug)
Aliskiren 150 mg
Intervention (Drug)
Amlodipine 2.5 mg
Intervention (Drug)
Placebo of Aliskiren
Intervention (Drug)
Placebo of Amlodipine
Intervention (Drug)
Placebo of Aliskiren/amlodipine 150/2.5 mg
Intervention (Drug)
Placebo of Aliskiren/amlodipine 150/5 mg
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01237223
Content hash
950c87463c0004a8c8cd079092b796873d9f220d28ab87234cf0688633fc1647